ストックスクリーナーアプリを入手
0.00
100.00%
-1.17
Ocuphire Pharma Inc (OCUP) 最新ニュース
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - Lelezard
Ocuphire Pharma Acquires Opus Genetics - Marketscreener.com
North Carolina gains public company with merger - The Business Journals
Ocuphire buys Opus Genetics, grows gene therapy pipeline - The Pharma Letter
Ocuphire Pharma Announces Acquisition of Opus Genetics - Vision Monday
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal - AOL
Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics - Yahoo Finance
OCUP stock touches 52-week low at $1.14 amid market challenges - Investing.com UK
Ocuphire and Opus Genetics merge to develop IRD gene therapy - Yahoo! Voices
Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders - Business Wire
Ocuphire Pharma acquires Opus Genetics in all-stock deal By Investing.com - Investing.com Australia
Ocuphire Pharma acquires Opus Genetics - MSN
Wilson Sonsini Advises Opus Genetics on IP Matters Related to Acquisition by Ocuphire Pharma - Wilson Sonsini
Ocuphire Pharma acquires Opus Genetics in all-stock deal - Investing.com
Presbyopia Market on Track for Major Expansion by 2034, - openPR
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics - The Globe and Mail
Mydriasis Market Forecasted to Surge in Coming Years, 2024-2034 - openPR
Ocuphire reports positive phase 3 results for eye treatment RYZUMVI - Investing.com
Ocuphire Pharma releases results from MIRA-2 and MIRA-3 clinical trials for phentolamine ophthalmic solution 0.75% for pharmacologically-induced mydriasis - Ophthalmology Times
Ocuphire reports positive phase 3 results for eye treatment RYZUMVI By Investing.com - Investing.com South Africa
Ocuphire Pharma Announces Publication of Full Phase 3 - GlobeNewswire
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology - StockTitan
OFS Credit Company, Inc. Prices Preferred Stock Offering - Business Wire
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
OFS Credit to offer preferred stock in public offering - MSN
Ratio Review: Analyzing Ocugen Inc (OCGN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Analyzing SOPHiA GENETICS (NASDAQ:SOPH) & Cyclo Therapeutics (NASDAQ:CYTH) - Defense World
Oaktree Specialty Lending director buys shares worth over $16,000 By Investing.com - Investing.com Canada
Is OCGN’s price to cash per share ratio a concern for investors? - US Post News
Option Care Health, Inc. (NASDAQ:OPCH) Position Increased by First Eagle Investment Management LLC - Defense World
Option Care Health, Inc. (NASDAQ:OPCH) Shares Sold by DekaBank Deutsche Girozentrale - Defense World
Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal
Opaleye Management Inc. Increases Stake in Codexis Inc. - Yahoo Finance
All the Doctor Odyssey guest stars we know so far - Hidden Remote
Mydriasis Treatment Market Booming Worldwide With Leading Key - openPR
Full approval of PBC therapy Ocaliva rejected by FDA committee in 10-1 vote - Liver Disease News
American Century Companies Inc. Raises Position in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World
Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS - PMLiVE
Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates - MSN
Ocuphire Pharma commences phase 3 trial for presbyopia treatment - Investing.com India
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia - Yahoo Finance UK
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial - GlobeNewswire
Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia - StockTitan
Ocuphire Pharma Inc [OCUP] Chief Scientific & Dev. Ofc. makes an insider purchase of 3,500 shares worth 6178.0. - Knox Daily
OCUP stock touches 52-week low at $1.15 amid market challenges - Investing.com
Analysts review Ocuphire Pharma Inc’s rating - Knox Daily
There is no way Ocuphire Pharma Inc (OCUP) can keep these numbers up - SETE News
Ocuphire Pharma Inc (OCUP) stock: A year of ups and downs - US Post News
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):